Frequency Therapeutics Stock
Small, molecular progenitor cells drugs
Sign up today and learn more about Frequency Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Frequency Therapeutics Stock
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. The lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.
Co-founder, President and Chief Executive Officer
David L. Lucchino
Co-founder and Vice President, Biology and Regenerative Medicine
Co-Founder, Co-chair of Scientific Advisory Board
Chief Operating Officer
Co-founder and Chief Scientific Officer
Chief Medical Officer
Senior Vice President, Drug Development and Technical Operations
TechCrunch - Jul, 28 2017A race is underway to repair our hearing — with medicine
TechCrunch - Feb, 22 2017Researchers devise method for regenerating hair cells to help reverse hearing loss
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase